drugset
drugset / Trial / NCT00017329

PS-341 in Treating Patients With Metastatic Kidney Cancer

NCT00017329 ↗

Phase 2 Completed Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab
Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic kidney cancer.

Timeline

Start
2001-04
Primary completion
2004-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — Intravenous

Indications

kidney cancer